Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEN1044
- Development stage
- Discontinued
- Lead developer
- Genmab
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
GEN1044 is a recombinant immunoglobulin G1 (IgG1) bispecific antibody developed using Genmab's DuoBody platform. It targets both the human T-cell surface antigen CD3 and the oncofetal antigen 5T4 (also known as trophoblast glycoprotein or TPBG). By binding to CD3 on T cells and 5T4 on tumor cells simultaneously, it crosslinks these cell types to trigger a cytotoxic T lymphocyte response against 5T4-expressing tumor cells. The expression of 5T4 is associated with increased invasiveness in various cancers. The drug was investigated for its antineoplastic and immunomodulatory activities in solid tumors but development has been discontinued[2][7][9].
- Other names
- anti-CD3/anti-5T4 bispecific antibody GEN1044DuoBody-CD3x5T4DuoBody-CD-3x5T4DuoBody-CD 3x5T4
02
Targets
TPBG (Trophoblast glycoprotein)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on GEN1044.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEN1044.